Cross-sectional analysis highlights serum irisin's role in distinguishing DR stages in T2DM patients, suggesting possible clinical implications.
Key Points
Serum irisin levels were higher in T2DM patients with diabetic retinopathy compared to those without, indicating a potential biomarker for the condition.
ICAM-1 levels showed no significant difference between retinopathy and non-retinopathy groups, but decreased in later stages of DR, pointing to possible inflammatory processes.
ROC analysis revealed that irisin effectively differentiates between non-proliferative and proliferative DR, with an area under the curve of 0.7.
The findings suggest roles for both irisin and ICAM-1 in the development and progression of diabetic retinopathy, warranting further investigation.